Valeo Financial Advisors LLC Cuts Stake in Johnson & Johnson $JNJ

Key Points

• Valeo Financial Advisors LLC has decreased its stake in Johnson & Johnson by 6.0%, now holding 121,636 shares valued at approximately $18.58 million.
• Johnson & Johnson reported $2.77 earnings per share for the last quarter, exceeding estimates and showing a 5.8% increase in revenue year-over-year.
• The company declared a quarterly dividend of $1.30 per share, representing a 2.8% dividend yield and a payout ratio of 55.61%.

Valeo Financial Advisors LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,636 shares of the company's stock after selling 7,750 shares during the quarter. Valeo Financial Advisors LLC's holdings in Johnson & Johnson were worth $18,580,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in JNJ. Highline Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the first quarter worth about $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson in the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson in the first quarter worth about $52,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.4%

Shares of JNJ opened at $188.95 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $455.06 billion, a P/E ratio of 20.21, a P/E/G ratio of 2.40 and a beta of 0.40. The firm has a fifty day moving average price of $177.04 and a 200-day moving average price of $163.18. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.92.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the business earned $2.82 EPS. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Analysts Set New Price Targets

A number of brokerages have recently commented on JNJ. HSBC lifted their target price on Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Finally, Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a "market perform" rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $189.88.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.